T he incidence of type 2 diabetes (T2D), recognized in 2006 as a global health priority by the United Nations, is increasing worldwide. According to the International Diabetes Federation, approximately 190 million people are affected by T2D worldwide, a number expected to nearly double in the coming 20 y. Traditionally an age-related disease, there is today an alarming increased prevalence of T2D in adolescent subjects, which calls urgently for preventive measures. T2D is diagnosed by the presence of elevated blood glucose concentrations, as measured by elevated fasting plasma glucose, 2-h postload glucose, and HbA1c levels.
T2D Is a Major Risk Factor for Cardiovascular Diseases
Often associated with an atherogenic dyslipidemia characterized by high triglyceride and low HDL levels (1), T2D is a major risk factor for cardiovascular diseases, which are the most common cause of death in patients with T2D (2) . Moreover, diabetes is also the main cause of loss of vision, renal failure, and amputation of the lower extremities (3). When T2D has been diagnosed, therapeutic intervention, in addition to lifestyle modifications, is necessary. However, the therapeutic armamentarium is relatively limited (4), consisting of drugs, in addition to insulin, including (i) α-glucosidase inhibitors, which decrease glucose absorption; (ii) metformin, which decreases hepatic glucose output; (iii) insulin secretagogues, such as sulfonylureas or glinides, which increase insulin secretion; (v) dipeptidyl peptidase 4, inhibitors, which stabilize the incretin GLP-1; and (vi) glitazones [thiazolidinediones (TZDs)], which are insulin sensitizers that activate the nuclear receptor peroxisome proliferator-activated receptor (PPAR)-γ. This latter class, although unique because of their insulin-sensitizing properties, has been fraught with side effects, resulting in the recommendation of restricted use or even, in certain countries, retraction from the market. However, there are no therapeutic alternatives to this class of insulin sensitizers. The discovery that TZDs are ligands for the nuclear receptor PPARγ (6) triggered investigations to decipher their molecular mechanisms of action as well as their biological effects in preclinical models, with the ultimate goal to develop new-generation
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agonists devoid of the side effects associated with TZD use. T2D is a complex disease, in which chronic hyperlipidemia and hyperglycemia lead to cumulative damaging effects on metabolic tissues, such as skeletal muscle, liver, and adipose tissues. Ectopic lipid accumulation in these tissues is probably one of the triggering events leading to insulin resistance (7) . The action of TZDs is thought to occur primarily via adipose tissue PPARγ favoring white adipose tissue expandability by promoting adipocyte differentiation, hence stimulating the mobilization of ectopic fat to white adipose depots (8, 9) . PPARγ in other tissues, such as macrophages and brain, also seems to contribute to the insulin-sensitizing effects of TZDs (10, 11) . In addition, TZDs may exert protective pancreatic and cardiovascular actions. However, these therapeutic benefits are clouded by adverse effects, including heart failure (12), bladder cancer (13), bone resorption, fluid retention, and weight gain (14) . 
The report by Weidner et al. (5) extends the SPPARM concept to a class of lowabundance, naturally occurring compounds, the amorfrutins, extracted from Glycyrrhiza foetida and Amorpha fruticosa, whose dried and peeled or unpeeled stems and roots are used in traditional Indian medicine or as a condiment, respectively. By using electrospray ionization MS, the authors identified 90 compounds interacting with PPARγ in a library of 8,000 purified compounds. Further selection identified four compounds that bind to PPARγ with ligand-binding affinities similar to pioglitazone, but partial activity. X-ray crystallography of one of these compounds, amorfrutin 1, revealed atomic interactions similar to those observed with partial PPARγ agonists, in agreement with the moderate ability of this compound to recruit archetypal transcription comodulators and to activate gene networks in cultured adipocytes. More surprisingly, the corepressor NCoR is dismissed at concentrations below the measured K d for PPARγ. However, these compounds appear not to be totally selective for PPARγ and display affinities, albeit approximately 2-log lower, for PPARα and PPARβ/δ, PPAR family members controlling, notably, fatty acid oxidation (22) . However, the authors did not report on the efficacy of PPARα and PPARβ/δ activation. Hence, it cannot be excluded that some of the reported properties are the results of pan-PPAR responses, as suggested by the induction of typical PPARα target genes, such as acyl-coA oxidase, in the liver of amorfrutin-treated animals, tested at doses as high as 100 mg/kg in vivo. In in vitro differentiated human adipocytes, amorfrutins activated a gene program with homologies to the one observed with rosiglitazone, albeit with less efficacy-a partial agonism signature-but repressed a "secretion-fatty acid metabolism" cluster unaffected by pioglitazone and rosiglitazone. Extensive analysis of potential side effects on hepatocytes (e.g., cell proliferation, genotoxicity) showed good safety responses in vitro, and these compounds displayed a good stability in absorption, distribution, metabolism, excretion, and toxicity assays.
Hence, the authors tested amorfrutin 1 in vivo in high-fat diet-fed and genetically obese db/db mice, showing that it increased insulin sensitivity to a similar extent as rosiglitazone, increased energy expenditure, and exerted antiinflammatory effects in liver and adipose tissue, without-in contrast to rosiglitazone-inducing fluid retention. Furthermore, liver steatosis was decreased upon amorfrutin treatment, but, as mentioned earlier, the authors could not exclude that this response was caused by the low affinity (but unknown efficacy) on PPARα activity (22) . From a mechanistic point of view, cdk5-induced PPARγ phosphorylation, an NCoR-dependent process (23) reported to reprogram PPARγ transcription activity (20) , was inhibited by rosiglitazone and amorfrutin in adipose tissues of high-fat diet-fed mice, a mechanism that could thus contribute to the antidiabetic activity of this compound. However, the authors did not address the activity of the amorfrutins on critical tissues such the kidney, which is believed to be involved in the fluid retention induced by TZDs (24); nor bone, for its osteoporotic activities. Nor did the authors perform extensive carcinogenicity tests (2 y/two species), a Food and Drug Administration requirement for long-term studies in humans. Hence, although amorfrutins appear promising, it is impossible at present to predict whether amorfrutins will have a better safety profile in humans than TZDs.
The identification of natural amorfrutins adds these compounds to the list of structurally novel PPARγ agonists with insulin-sensitizing effects and which are devoid of a number of previously identified side effects in preclinical models. Although underlining the richness and potential of exploring natural compound libraries, off-target effects should be considered for each molecule regardless of its origin. It is worth noting that amorfrutin 1 exerts anti-NF-κB activity (25) , prevents iNOS expression in MCF7 breast cancer cells, inhibits the corticotropin releasing factor-binding protein, inhibits the cysteine protease ATGB4, and also targets the photoreceptor-specific nuclear receptor NR2E3 (26). Some of these properties are shared with other (2-phenylethyl)benzoic acid derivatives. Rosiglitazone and pioglitazone bind to the mitochondrial mitoNEET protein (27) and modulate protein-protein interaction between Keap1 and Nrf2. All these effects may contribute to the beneficial effect on glucose and lipid homeostasis, but could also provoke potential side effects. Thus, screening strategies for novel PPARγ modulators should not only include extensive testing in preclinical models for efficacy and side effects, but also assessment of efficacy in clinical studies in humans. Unfortunately, none of the SPPARMs so far reported have stood this final test in humans. Although amorfrutins raise the hope that this goal can be achieved, further testing in appropriate animal models and, ultimately, in man will be required. If the results were to be positive, amorfrutins could represent a novel generation of nutraceutical agents that are useful for not only the treatment, but also possibly the prevention, of T2D.
